Y-mAbs Therapeutics, Inc.
NASDAQ:YMAB
4.91 (USD) • At close March 12, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 87.685 | 84.819 | 65.267 | 34.897 | 20.75 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 15.251 | 11.416 | 7.567 | 2.514 | 2.203 | 0.166 | 0.029 | 0 | 0 |
| Gross Profit
| 72.434 | 73.403 | 57.7 | 32.383 | 18.547 | -0.166 | -0.029 | 0 | 0 |
| Gross Profit Ratio
| 0.826 | 0.865 | 0.884 | 0.928 | 0.894 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 48.99 | 54.219 | 91.572 | 93.245 | 93.697 | 63.492 | 34.269 | 14.307 | 13.855 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 44.785 | 19.512 | 8.961 | 4.937 | 3.184 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 54.645 | 44.856 | 60.939 | 54.571 | 44.785 | 19.512 | 8.961 | 4.937 | 3.184 |
| Other Expenses
| 0 | 0 | 0 | 62.01 | -2.203 | 0 | -0.044 | 0.083 | -0.018 |
| Operating Expenses
| 103.635 | 99.075 | 152.511 | 147.816 | 138.482 | 83.004 | 43.23 | 19.244 | 17.039 |
| Operating Income
| -31.201 | -25.672 | -94.811 | -115.433 | -119.935 | -83.004 | -43.23 | -19.244 | -17.039 |
| Operating Income Ratio
| -0.356 | -0.303 | -1.453 | -3.308 | -5.78 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 1.389 | 4.806 | -0.757 | 60.158 | 0.598 | 1.976 | -0.044 | 0.083 | -0.018 |
| Income Before Tax
| -29.812 | -20.866 | -95.568 | -55.275 | -119.337 | -81.028 | -43.274 | -19.161 | -17.057 |
| Income Before Tax Ratio
| -0.34 | -0.246 | -1.464 | -1.584 | -5.751 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -0.146 | 0.561 | 0.757 | 1.07 | -0.994 | -2.142 | -0.044 | -19.244 | -17.039 |
| Net Income
| -29.666 | -21.427 | -96.325 | -56.345 | -118.343 | -78.886 | -43.274 | -19.161 | -17.057 |
| Net Income Ratio
| -0.338 | -0.253 | -1.476 | -1.615 | -5.703 | 0 | 0 | 0 | 0 |
| EPS
| -0.67 | -0.49 | -2.2 | -1.3 | -2.95 | -2.24 | -1.5 | -0.58 | -0.51 |
| EPS Diluted
| -0.67 | -0.49 | -2.2 | -1.3 | -2.95 | -2.24 | -1.5 | -0.58 | -0.51 |
| EBITDA
| -31.201 | -24.937 | -94.729 | -54.493 | -119.539 | -82.838 | -43.201 | 0.083 | -0.018 |
| EBITDA Ratio
| -0.356 | -0.294 | -1.453 | -3.308 | -5.674 | 0 | 0 | 0 | 0 |